Although further studies are required to clarify the detailed mechanisms of chronic pharmacological MGAT2 inhibition, our findings may inform the development of MGAT2‐targeting therapeutic drugs for obesity and obesity‐related diseases. The gene discussed is MGAT2; the disease is obesity due to melanocortin 4 receptor deficiency.